^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Triple Negative Breast Cancer
    Drug:epirubicin (Topoisomerase II inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Ann Transl Med
    Title:

    PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

    Published date:
    03/05/2021
    Excerpt:
    Epirubicin was used as the chemotherapeutic agent....Further, xenograft tumors grew faster in NOD/SCID mice injected with mutated cell lines than in control group, suggesting that PIK3CA mutation caused chemotherapy resistance....PIK3CA mutation confers resistance to chemotherapy in TNBC by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
    DOI:
    10.21037/atm-21-698